Literature DB >> 24122741

Which approach is better: bilateral versus unilateral thalamic deep brain stimulation in patients with fragile X-associated tremor ataxia syndrome.

R Mehanna1, I Itin.   

Abstract

Fragile X-associated tremor ataxia syndrome (FXTAS) is a relatively recently described condition that is frequently misdiagnosed as essential tremor and then occasionally treated as such with deep brain stimulation (DBS) to the nucleus ventralis intermedius of the thalamus (Vim). Reports of ataxia worsening after bilateral Vim DBS in FXTAS patients are conflicting, and only five FXTAS patients treated with Vim DBS for intractable tremor have been reported in the literature, three of whom having undergone a bilateral procedure. We report a patient who underwent a staged Vim DBS procedure, with excellent contralateral hand tremor control and no worsening of ataxia after the first procedure, but immediate worsening of his ataxia after the second one, arguing in favor of a unilateral surgical approach for intractable tremor in FXTAS.

Entities:  

Mesh:

Year:  2014        PMID: 24122741     DOI: 10.1007/s12311-013-0530-7

Source DB:  PubMed          Journal:  Cerebellum        ISSN: 1473-4222            Impact factor:   3.847


  15 in total

1.  Treatment of fragile X-associated tremor/ataxia syndrome with unilateral deep brain stimulation.

Authors:  Tao Xie; Robert Goodman; Nina Browner; Elizabeth Haberfeld; Linda Winfield; Jill Goldman; Blair Ford
Journal:  Mov Disord       Date:  2012-02-16       Impact factor: 10.338

2.  Intention tremor, parkinsonism, and generalized brain atrophy in male carriers of fragile X.

Authors:  R J Hagerman; M Leehey; W Heinrichs; F Tassone; R Wilson; J Hills; J Grigsby; B Gage; P J Hagerman
Journal:  Neurology       Date:  2001-07-10       Impact factor: 9.910

3.  Treatment of fragile-X-associated tremor/ataxia syndrome with deep brain stimulation.

Authors:  Joseph M Ferrara; Octavian R Adam; William G Ondo
Journal:  Mov Disord       Date:  2009-01-15       Impact factor: 10.338

4.  Altered zinc transport disrupts mitochondrial protein processing/import in fragile X-associated tremor/ataxia syndrome.

Authors:  Eleonora Napoli; Catherine Ross-Inta; Sarah Wong; Alicja Omanska-Klusek; Cedrick Barrow; Christine Iwahashi; Dolores Garcia-Arocena; Danielle Sakaguchi; Elizabeth Berry-Kravis; Randi Hagerman; Paul J Hagerman; Cecilia Giulivi
Journal:  Hum Mol Genet       Date:  2011-05-10       Impact factor: 6.150

5.  Intrafamilial variability in fragile X-associated tremor/ataxia syndrome.

Authors:  Nils Peters; Christoph Kamm; Friedrich Asmus; Elke Holinski-Feder; Eduard Kraft; Martin Dichgans; Roland Brüning; Thomas Gasser; Kai Bötzel
Journal:  Mov Disord       Date:  2006-01       Impact factor: 10.338

6.  Premutation and intermediate-size FMR1 alleles in 10572 males from the general population: loss of an AGG interruption is a late event in the generation of fragile X syndrome alleles.

Authors:  C Dombrowski; S Lévesque; M L Morel; P Rouillard; K Morgan; F Rousseau
Journal:  Hum Mol Genet       Date:  2002-02-15       Impact factor: 6.150

7.  Evidence of mitochondrial dysfunction in fragile X-associated tremor/ataxia syndrome.

Authors:  Catherine Ross-Inta; Alicja Omanska-Klusek; Sarah Wong; Cedrick Barrow; Dolores Garcia-Arocena; Christine Iwahashi; Elizabeth Berry-Kravis; Randi J Hagerman; Paul J Hagerman; Cecilia Giulivi
Journal:  Biochem J       Date:  2010-08-01       Impact factor: 3.857

8.  FXTAS: new insights and the need for revised diagnostic criteria.

Authors:  Emmanuelle Apartis; Anne Blancher; Wassilios G Meissner; Lucie Guyant-Maréchal; David Maltête; Thomas De Broucker; André-Pierre Legrand; Hichem Bouzenada; Hung Tran Thanh; Magali Sallansonnet-Froment; Adrien Wang; François Tison; Carole Roué-Jagot; Frédéric Sedel; Perrine Charles; Sandra Whalen; Delphine Héron; Stéphane Thobois; Alice Poisson; Gaetan Lesca; Anne-Marie Ouvrard-Hernandez; Valérie Fraix; Stephane Palfi; Marie-Odile Habert; Bertrand Gaymard; Jean-Claude Dussaule; Pierre Pollak; Marie Vidailhet; Alexandra Durr; Jean-Claude Barbot; Véronique Gourlet; Alexis Brice; Mathieu Anheim
Journal:  Neurology       Date:  2012-10-17       Impact factor: 9.910

9.  Penetrance of the fragile X-associated tremor/ataxia syndrome in a premutation carrier population.

Authors:  Sébastien Jacquemont; Randi J Hagerman; Maureen A Leehey; Deborah A Hall; Richard A Levine; James A Brunberg; Lin Zhang; Tristan Jardini; Louise W Gane; Susan W Harris; Kristin Herman; James Grigsby; Claudia M Greco; Elizabeth Berry-Kravis; Flora Tassone; Paul J Hagerman
Journal:  JAMA       Date:  2004-01-28       Impact factor: 56.272

10.  Prevalence of carriers of premutation-size alleles of the FMRI gene--and implications for the population genetics of the fragile X syndrome.

Authors:  F Rousseau; P Rouillard; M L Morel; E W Khandjian; K Morgan
Journal:  Am J Hum Genet       Date:  1995-11       Impact factor: 11.025

View more
  4 in total

1.  Deep brain stimulation in uncommon tremor disorders: indications, targets, and programming.

Authors:  Carlo Alberto Artusi; Ashar Farooqi; Alberto Romagnolo; Luca Marsili; Roberta Balestrino; Leonard L Sokol; Lily L Wang; Maurizio Zibetti; Andrew P Duker; George T Mandybur; Leonardo Lopiano; Aristide Merola
Journal:  J Neurol       Date:  2018-03-06       Impact factor: 4.849

Review 2.  Fragile X-associated tremor/ataxia syndrome - features, mechanisms and management.

Authors:  Randi J Hagerman; Paul Hagerman
Journal:  Nat Rev Neurol       Date:  2016-06-24       Impact factor: 42.937

3.  Deep brain stimulation for tremor associated with underlying ataxia syndromes: a case series and discussion of issues.

Authors:  Genko Oyama; Amanda Thompson; Kelly D Foote; Natlada Limotai; Muhammad Abd-El-Barr; Nicholas Maling; Irene A Malaty; Ramon L Rodriguez; Sankarasubramoney H Subramony; Tetsuo Ashizawa; Michael S Okun
Journal:  Tremor Other Hyperkinet Mov (N Y)       Date:  2014-07-09

Review 4.  Deep brain stimulation for the treatment of uncommon tremor syndromes.

Authors:  Adolfo Ramirez-Zamora; Michael S Okun
Journal:  Expert Rev Neurother       Date:  2016-06-09       Impact factor: 4.618

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.